Alentis has completed an oversubscribed Series D round. The round was led by Orbimed and co-led by Novo Holdings and Jeito Capital, with contributions from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital and Avego Bioscience Capital.
The funds will be used to support the clinical development of Alentis’ pipeline of drugs targeted at solid tumours.
More details on the Alentis website.
Sundew has completed a financing, with EIFO, The Yield Lab Europe and SOSV providing the funds.
The raise was covered (in Danish) by KapitalWatch (payroll).
The Danish pharma giant joins Roche, J&J, CSL Behring, Pureos, CMS, Roivant and Bridge Biotherapeutics in supporting BaseLaunch’s development of innovative biotech companies.
More details on the BaseLaunch website.
Alentis is a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. They announced today the first patient dosed in a Phase 2 clinical trial of lixudebart for the treatment of organ fibrosis.
For more details, click here.
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
More details on the BaseLaunch website.
American distributor, LiveAquaria, has launched ‘ProtoPro’ the world’s first product based on Sundew’s proprietary active: Biokos™.
More details on the Sundew website.
Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the US Food and Drug Administration (FDA) has granted Fast Track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1-positive HNSCC.
Details here.
NPS have announced that they have successfully completed their consultation with FDA on their high anti-oxidant purple tomato.
The company can now launch a range of purple tomato products, including fresh tomatoes and seeds for home gardeners.
See the NPS press release here.
Chosa oncology has published results from a clinical phase 2 trial of their liposomal cisplatin formulation for breast cancer using a predictive biomarker.
More details on the Chosa website.
Alentis Therapeutics has secured the investment to fund clinical programs on its two anti-Claudin-1 antibodies for organ fibrosis and CLDN1 positive tumours.
The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.
More details on the BaseLaunch website.